BR112016027383A8 - derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação - Google Patents

derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação

Info

Publication number
BR112016027383A8
BR112016027383A8 BR112016027383A BR112016027383A BR112016027383A8 BR 112016027383 A8 BR112016027383 A8 BR 112016027383A8 BR 112016027383 A BR112016027383 A BR 112016027383A BR 112016027383 A BR112016027383 A BR 112016027383A BR 112016027383 A8 BR112016027383 A8 BR 112016027383A8
Authority
BR
Brazil
Prior art keywords
combination
pharmaceutical composition
naphthyridinedione
derivatives
naphthyridinedione derivatives
Prior art date
Application number
BR112016027383A
Other languages
English (en)
Other versions
BR112016027383A2 (pt
Inventor
Spanka Carsten
Reinhardt Juergen
Schmiedeberg Niko
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016027383A2 publication Critical patent/BR112016027383A2/pt
Publication of BR112016027383A8 publication Critical patent/BR112016027383A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados de naftiridinadiona. a presente invenção refere-se ao composto da fórmula (i') (i') ou um sal do mesmo, em que os substituintes são conforme definidos no relatório descritivo; a sua preparação, a seu uso como medicamento e aos medicamentos que o compreendem.
BR112016027383A 2014-06-03 2015-06-02 derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação BR112016027383A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14170976 2014-06-03
PCT/IB2015/054174 WO2015186063A1 (en) 2014-06-03 2015-06-02 Naphthyridinedione derivatives

Publications (2)

Publication Number Publication Date
BR112016027383A2 BR112016027383A2 (pt) 2017-08-15
BR112016027383A8 true BR112016027383A8 (pt) 2021-07-20

Family

ID=50841689

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027383A BR112016027383A8 (pt) 2014-06-03 2015-06-02 derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação

Country Status (28)

Country Link
US (2) US10138232B2 (pt)
EP (1) EP3152209B1 (pt)
JP (2) JP6343034B2 (pt)
KR (1) KR101905295B1 (pt)
CN (1) CN106459043B (pt)
AP (1) AP2016009545A0 (pt)
AR (1) AR100706A1 (pt)
AU (2) AU2015270125B2 (pt)
BR (1) BR112016027383A8 (pt)
CA (1) CA2950724A1 (pt)
CL (1) CL2016003081A1 (pt)
CR (1) CR20160565A (pt)
CU (1) CU24438B1 (pt)
EA (1) EA030374B1 (pt)
EC (1) ECSP16096831A (pt)
ES (1) ES2731802T3 (pt)
GT (1) GT201600252A (pt)
IL (1) IL248773B (pt)
MX (1) MX2016015856A (pt)
MY (1) MY178379A (pt)
PE (1) PE20170086A1 (pt)
PH (2) PH12016502293A1 (pt)
SG (1) SG11201609209YA (pt)
SV (1) SV2016005331A (pt)
TN (1) TN2016000490A1 (pt)
TW (1) TWI688565B (pt)
UY (1) UY36150A (pt)
WO (1) WO2015186063A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015186061A1 (en) * 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives
JP6560257B2 (ja) * 2014-06-03 2019-08-14 ノバルティス アーゲー ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体
TN2016000490A1 (en) 2014-06-03 2018-04-04 Novartis Ag Naphthyridinedione derivatives.
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
WO2020022375A1 (ja) 2018-07-24 2020-01-30 ソニーセミコンダクタソリューションズ株式会社 半導体装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ ５−デアザフラビン系化合物を有効成分とする制癌剤
JP2989871B2 (ja) * 1989-08-30 1999-12-13 大日本製薬株式会社 三環式化合物
DE4035479A1 (de) 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
US5908930A (en) 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US6016875A (en) * 1998-02-10 2000-01-25 Case Corporation Gain adaptation control for hydraulic systems
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
HUE031794T2 (en) 2003-04-11 2017-08-28 Ptc Therapeutics Inc 1,2,4-oxadiol-benzoic acid compounds and their use for nonsense suppression and disease treatment
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2810655C (en) * 2004-06-24 2013-12-10 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CN101076703A (zh) * 2004-10-13 2007-11-21 Ptc医疗公司 用于无义抑制的化合物及其使用方法
ES2594343T3 (es) 2006-04-03 2016-12-19 Technion Research & Development Foundation Limited Aminoglucósidos novedosos y usos de los mismos en el tratamiento de trastornos genéticos
AU2007288198A1 (en) 2006-08-23 2008-02-28 Neurogen Corporation Haloalkyl-substituted pyrimidinone derivatives
CN101687883B (zh) 2007-05-25 2012-05-23 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
WO2009086303A2 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
EP2600865B1 (en) * 2010-08-05 2018-11-14 Université de Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
AU2013358591B2 (en) 2012-12-13 2016-08-25 Novartis Ag Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors
TN2016000490A1 (en) 2014-06-03 2018-04-04 Novartis Ag Naphthyridinedione derivatives.
JP6560257B2 (ja) 2014-06-03 2019-08-14 ノバルティス アーゲー ピリミド［４，５−ｂ］キノリン−４，５（３Ｈ，１０Ｈ）−ジオン誘導体
WO2015186061A1 (en) 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives

Also Published As

Publication number Publication date
PH12016502293B1 (en) 2017-02-13
CN106459043B (zh) 2018-12-28
CU20160182A7 (es) 2017-03-03
MX2016015856A (es) 2017-04-25
CL2016003081A1 (es) 2017-06-09
PH12016502293A1 (en) 2017-02-13
SG11201609209YA (en) 2016-12-29
EP3152209B1 (en) 2019-03-20
EA030374B1 (ru) 2018-07-31
CU24438B1 (es) 2019-09-04
GT201600252A (es) 2018-12-18
ES2731802T3 (es) 2019-11-19
US20150344476A1 (en) 2015-12-03
PE20170086A1 (es) 2017-03-17
JP2018138609A (ja) 2018-09-06
SV2016005331A (es) 2018-08-20
KR101905295B1 (ko) 2018-10-05
US20190248784A1 (en) 2019-08-15
IL248773B (en) 2019-12-31
TN2016000490A1 (en) 2018-04-04
EA201692270A1 (ru) 2017-03-31
CA2950724A1 (en) 2015-12-10
CN106459043A (zh) 2017-02-22
US10138232B2 (en) 2018-11-27
PH12018501709A1 (en) 2019-08-14
JP6343034B2 (ja) 2018-06-13
BR112016027383A2 (pt) 2017-08-15
CR20160565A (es) 2017-03-10
UY36150A (es) 2016-01-29
IL248773A0 (en) 2017-01-31
AU2018200421A1 (en) 2018-02-08
AP2016009545A0 (en) 2016-11-30
AU2015270125A1 (en) 2016-11-24
TW201625610A (zh) 2016-07-16
ECSP16096831A (es) 2018-04-30
TWI688565B (zh) 2020-03-21
MY178379A (en) 2020-10-09
AU2015270125B2 (en) 2017-10-19
JP2017516821A (ja) 2017-06-22
AR100706A1 (es) 2016-10-26
KR20160148679A (ko) 2016-12-26
EP3152209A1 (en) 2017-04-12
WO2015186063A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112017002053A2 (pt) composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto
BR112018075260A2 (pt) inibidores da interação de menina-llm
BR112018012707A2 (pt) inibidores da interação de menin-mll
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
BR112016013861A2 (pt) conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica
BR112018074972A2 (pt) derivados de adenosina para uso no tratamento de câncer
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BR112018011817A2 (pt) derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112017010645A2 (pt) derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos
ECSP15000868A (es) Derivados de estra–1,3,5(10),16–tetraeno 3–sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017001334A2 (pt) compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende
BR112017022757A2 (pt) derivados do pirazol úteis como inibidores da proteína ativadora da 5-lipoxigenase (flap)
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112015001207A8 (pt) derivados de carbamato/ureia, seus usos, composição farmacêutica, forma livre e seu método de preparação
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112017027762A2 (pt) compostos de c,o-espiro aril glicosídeo, preparação para os mesmos e uso dos mesmos
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time